로딩 중…
StockDiggingStockDigging

Pfizer Inc.

PFE· NYSE
$25.05+0.16%
2026-08-03

Financials

Valuation Metrics

Pfizer Inc.'s Market Cap is $142.77B. At end of 2025 it was $139.17B. Ranked #111 of 3,112 in US market (top 4%), #71 of 1,667 on NYSE (top 4%), #10 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 4%) by Market Cap.

Investment Metrics(as of 2026-08-03)

MetricValue
Size
Market Cap$142.77B
Revenue$63.31B
Net Income$7.49B
Total Assets$207.62B
Net Assets$90.10B
Employees75,000
Value
P/E19.06x
P/B1.58x
P/S2.25x
EV/EBITDA12.27x
FCF Yield6.64%
Profitability
ROE8.31%
ROA3.61%
Op. Margin23.45%
Revenue Growth5.37%
Earnings Growth-9.40%
Financial Health
Debt Ratio130.09%
Total Debt$64.45B
FCF$9.48B
Cash$1.70B
Current Ratio1.25x
Net Debt/EBITDA3.75x
Dividend
Div. Yield6.85%
Div. Growth2.38%
Performance
1Y Return10.34%
1M Return3.00%
From 52W High-12.85%
1Y MDD-17.09%
Trading
Volume34,699,310 shares
Trading Value$871M
Per Share
EPS$1.37
BPS$15.22

Company Info

CEO Dr. Albert Bourla D.V.M., Ph.D.
Employees 75,000
HQ New York, United States

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.